The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL
Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, presents results from the Phase III TRANSFORM trial (NCT03575351), which is assessing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) with salvage chemotherapy followed by autologous stem cell transplant (autoSCT) for second-line treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The study reported superior event-free survival (EFS), progression-free survival (PFS) and complete response (CR) rates in the liso-cel group, with a manageable toxicity profile for liso-cel. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Seattle Genetics: Research Funding; BMS, AbbVie, Genentech, Epizyme, BeiGene, Kymera, Bluebird Bio, Incyte, Kite Pharma, Genmab, Ono Pharma, Mustang Bio, MorphoSys, Regeneron, Century, AstraZeneca, Lilly, Janssen: Consultancy.
